Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company focused on developing "MasterKey" therapies that address broad families of oncogenic mutations. Their approach aims to expand the addressable patient population by offering a single solution for multiple mutations, overcoming resistance, minimizing toxicities, and being brain penetrant to treat CNS diseases. Their efforts are concentrated on non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Black Diamond has generated two clinical-stage MasterKey drug candidates: BDTX-1535 for patients with EGFR-mutant NSCLC or GBM, and BDTX-4933 for patients with KRAS-mutant NSCLC or RAF/RAS-mutant tumors. They are dedicated to providing people living with cancer the opportunity to experience longer, healthier, and more active lives, and support patient advocacy groups focused on NSCLC and GBM.

Black Diamond Therapeutics is a clinical-stage oncology company dedicated to providing people living with cancer the opportunity for longer, healthier lives by developing innovative "MasterKey" therapies. Their approach focuses on targeting broad families of oncogenic mutations, which expands the addressable patient population and offers one solution for many mutations. They strive to overcome resistance, minimize toxicities, and develop brain-penetrant therapies to address CNS diseases, with a particular focus on non-small cell lung cancer and glioblastoma.

Black Diamond Therapeutics prioritizes a culture of collaboration, innovation, and patient-centricity. They foster a dynamic and supportive environment where employees are encouraged to share ideas and work together towards a common goal of defeating cancer resistance. The company values diversity, inclusion, and respect, creating a workplace where individuals feel empowered and valued. This culture is reflected in their commitment to developing therapies that expand the scope of treatment for patients with cancer, while supporting advocacy groups and patient communities.